Segment Data

6 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Segment Data

Segment Data

The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.

Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.

	Three Months Ended March 31,
(Millions of dollars)	2024						2023
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	662	$	445	$	1,107	$	616	$	454	$	1,070
Medication Management Solutions	609		162		772		550		173		723
Pharmaceutical Systems	157		413		570		173		394		567
Total segment revenues	$	1,429	$	1,020	$	2,449	$	1,339	$	1,022	$	2,360
Life Sciences
Integrated Diagnostic Solutions	$	437	$	490	$	927	$	422	$	466	$	888
Biosciences	142		235		377		159		228		386
Total segment revenues	$	579	$	724	$	1,304	$	581	$	694	$	1,275
Interventional
Surgery	$	287	$	92	$	379	$	295	$	86	$	381
Peripheral Intervention	264		225		489		256		213		468
Urology and Critical Care	347		78		424		263		74		336
Total segment revenues	$	898	$	395	$	1,292	$	813	$	373	$	1,186
Total Company revenues	$	2,906	$	2,139	$	5,045	$	2,733	$	2,088	$	4,821

	Six Months Ended March 31,
(Millions of dollars)	2024						2023
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	1,301	$	857	$	2,159	$	1,235	$	873	$	2,109
Medication Management Solutions	1,203		315		1,518		1,114		316		1,430
Pharmaceutical Systems	285		717		1,002		292		684		976
Total segment revenues	$	2,789	$	1,890	$	4,679	$	2,642	$	1,873	$	4,515
Life Sciences
Integrated Diagnostic Solutions	$	881	$	959	$	1,840	$	930	$	911	$	1,841
Biosciences	285		466		752		296		440		736
Total segment revenues	$	1,166	$	1,426	$	2,592	$	1,226	$	1,351	$	2,577
Interventional
Surgery	$	568	$	181	$	748	$	582	$	162	$	744
Peripheral Intervention	498		444		943		492		410		902
Urology and Critical Care	634		156		789		522		148		670
Total segment revenues	$	1,699	$	781	$	2,480	$	1,595	$	720	$	2,315
Total Company revenues	$	5,655	$	4,096	$	9,751	$	5,462	$	3,944	$	9,407

Segment income for the three and six-month periods was as follows:

	Three Months Ended March 31,				Six Months Ended March 31,
(Millions of dollars)	2024		2023		2024		2023
Income Before Income Taxes
Medical	$	662	$	641	$	1,197	$	1,195
Life Sciences	415		394		787		827
Interventional	388		297		679		598
Total Segment Operating Income	1,465		1,333		2,663		2,621
Integration and restructuring expense	(101)		(62)		(176)		(106)
Net interest expense	(99)		(108)		(176)		(204)
Other unallocated items (a)	(632)		(635)		(1,320)		(1,301)
Total Income Before Income Taxes	$	633	$	529	$	991	$	1,009

(a)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.